Ed Reznik, PhD

Assistant Attending

Ed Reznik, PhD

Assistant Attending
Share
Share
Ed Reznik, Assistant Attending

Office Phone

646-608-7553

Education

Boston University

Ed Reznik is an Assistant Attending Computational Oncologist in the Department of Epidemiology and Biostatistics, and is affiliated with the Marie-Josée and Henry R. Kravis Center for Molecular Oncology and the Urology Service. His research applies computational and informatic approaches to address basic and translational questions in mitochondrial genetics and metabolic dysregulation in cancer. The long-term goal of his research program is understanding how metabolic phenomena support the initiation, progression, and therapeutic susceptibility of tumors. Originally trained as an engineer, he has applied tools from optimization theory to develop predictive, genome-scale models of bacterial and eukaryotic metabolism from high-throughput metabolic data. Using data from The Cancer Genome Atlas Consortium, Dr. Reznik produced the first large-scale assessment of mitochondrial DNA copy number variation across solid tumor types. In parallel, he has developed integrative informatic approaches to study solid tumor metabolism through analysis of metabolomic and transcriptomic data, including the publication of the first atlas of metabolomic changes across tumor types. He is also an active member of the Kidney Cancer Working Group and contributes to the analysis of genomic, metabolomic, and immunological data related to kidney cancer biology and management.

Publications

Selected peer-reviewed publications:

Tang C, Xie AX, Liu EM, Kuo F, Kim M, DiNatale RG, Golkaram M, Chen YB, Gupta S, Motzer RJ, Russo P, Coleman J, Carlo MI, Voss MH, Kotecha RR, Lee CH, Tansey W, Schultz N, Hakimi AA, Reznik E. Immunometabolic coevolution defines unique microenvironmental niches in ccRCC. Cell Metab. 2023 Aug 8;35(8):1424-1440.e5. doi: 10.1016/j.cmet.2023.06.005. Epub 2023 Jul 5. PMID: 37413991.

Benedetti E, Liu EM, Tang C, Kuo F, Buyukozkan M, Park T, Park J, Correa F, Hakimi AA, Intlekofer AM, Krumsiek J, Reznik E. A multimodal atlas of tumour metabolism reveals the architecture of gene-metabolite covariation. Nat Metab. 2023 Jun;5(6):1029-1044. doi: 10.1038/s42255-023-00817-8. Epub 2023 Jun 19. PMID: 37337120; PMCID: PMC10290959.

Posada Calderon L, Eismann L, Reese SW, Reznik E, Hakimi AA. Advances in Imaging-Based Biomarkers in Renal Cell Carcinoma: A Critical Analysis of the Current Literature. Cancers (Basel). 2023 Jan 5;15(2):354. doi: 10.3390/cancers15020354. PMID: 36672304; PMCID: PMC9856305.

Golkaram M, Kuo F, Gupta S, Carlo MI, Salmans ML, Vijayaraghavan R, Tang C, Makarov V, Rappold P, Blum KA, Zhao C, Mehio R, Zhang S, Godsey J, Pawlowski T, DiNatale RG, Morris LGT, Durack J, Russo P, Kotecha RR, Coleman J, Chen YB, Reuter VE, Motzer RJ, Voss MH, Liu L, Reznik E, Chan TA, Hakimi AA. Spatiotemporal evolution of the clear cell renal cell carcinoma microenvironment links intra-tumoral heterogeneity to immune escape. Genome Med. 2022 Dec 19;14(1):143. doi: 10.1186/s13073-022-01146-3. PMID: 36536472; PMCID: PMC9762114.

Rappold PM, Vuong L, Leibold J, Chakiryan NH, Curry M, Kuo F, Sabio E, Jiang H, Nixon BG, Liu M, Berglund AE, Silagy AW, Mascareno EA, Golkaram M, Marker M, Reising A, Savchenko A, Millholland J, Chen YB, Russo P, Coleman J, Reznik E, Manley BJ, Ostrovnaya I, Makarov V, DiNatale RG, Blum KA, Ma X, Chowell D, Li MO, Solit DB, Lowe SW, Chan TA, Motzer RJ, Voss MH, Hakimi AA. A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discov. 2022 Oct 5;12(10):2308-2329. doi: 10.1158/2159-8290.CD-21-0925. PMID: 35758895; PMCID: PMC9720541.